MEDICINAL CHEMISTRY
STRATEGY MEETING EAST COAST USA 2024

Wednesday, 13th November 2024 | **Le Méridien Boston Cambridge**

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Featuring Industry Leaders and Decision Makers:

Alex Nivorozhkin
Chief Scientific Officer
Cybin

Muneto Mogi
Global Head, Global Discovery Chemistry
Novartis Institutes for BioMedical Research (NIBR)

Jennifer Petter
Sounder & Chief Scientific Officer
Arrakis Therapeutics

Ed Olhava
Senior Vice President, Preclinical Development
IFM Therapeutics

Blaise Lippa
Chief Scientific Officer
Morphic Therapeutic

Jennifer Petter
Founder & Chief Scientific Officer
Arrakis Therapeutics

Rich Heidebrecht
Vice President of Research and Development
Glycologix

Monica Schenone
Senior Director, Head Of Chemical Biology and Proteomics
Pfizer

21 ROUNDTABLE DISCUSSIONS

6 TRACKS

3 KEYNOTE PRESENTATIONS

1 PANEL DISCUSSION

1 LOCATION

What Makes Our Strategy Meetings So Unique?

Proud to Partner with:

WuXi AppTec | Sai | iktos | CDD Collaborative Drug Discovery | Piramal Pharma Solutions | revvity signals | PELAGO BIOSCIENCE | sapio sciences | evotec | REDX GLEAD | PARTEX | aragen | BIODURO-SUNDIA | inductivebio | eMolecules | NovAliX | SynSmart | SUVEN PHARMA | JUBILANT BIOSYS | LAXAI

PROVENTA INTERNATIONAL
proventainternational.com
UK: +44 (0)20 3314 0100
US: +1 (617) 614 0377
info@proventainternational.com
Proventa International
@proventaintl
@proventainternational

Proventa International's Strategy Meetings are a completely unique experience.

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2024

Wednesday, 13th November 2024 · Le Méridien Boston Cambridge

We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.

Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format

ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.

INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

Seniority of Attendees

- Director Level
- President / VP
- Department Head
- Other
- Team Lead
- C-Level
- Scientist
- Academia
- Manager
- Biology Specialist



Medicinal Chemistry

- Medicinal Chemistry
- R&D
- Drug Discovery
- Computational Chemistry
- Cheminformatics
- CMC
- External Innovation
- Pre-Clinical
- Artificial Intelligence

Meet Investors

- Venture Capital
- Private Equity
- Large Pharma/Biotech
- Corporate Venture Capital
- Institutional
- High Net Worth
- Family Office/Private Wealth
- Government Organisation/
- Sovereign Wealth Fund
- Angel

proventainternational.com
UK: +44 (0)20 3314 0100
US: +1 (617) 614 0377
info@proventainternational.com
Proventa International
@proventaintl
@proventainternational
PROVENTA INTERNATIONAL

Facilitator Faculty

Dr. Tao Guo
SVP and Head of WuXi Chemistry – Research Chemistry Services Business Development and Integrated Program Management
WuXi AppTec

Vicky Steadman
Vice President Business Development and Integrated Partnerships
Sai Life Sciences

Kelly Barret
Director of Discovery Business Development
Sai Life Sciences

Carlos Pedraza
AVP Biology & Site Head
Sai Life Sciences

Zev Wisotsky
Director, New Modality Drug Discovery Solutions
Revvity Signals

Itta MacNevin
SVP, Head of Business Development North America
Evotec

Patrick O'Mara
Associate Director of Research Informatics
Photys Therapeutics

Alex Nivorozhkin
Chief Scientific Officer
Cybin

Allen Hopper
VP Drug Discovery
Lucy Therapeutics

Benoit Moreau
Head of Medicinal Chemistry
Remix Therapeutics

Blaise Lippa
Chief Scientific Officer
Morphic Therapeutic

Brian Sparling
Director, Head of Medicinal Chemistry
Accent Therapeutics

Bruce Ellsworth
Head of Oncology East & BBRC Medicinal Chemistry
Bristol Myers Squibb

Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

Ed Olhava
Senior Vice President, Preclinical Development
IFM Therapeutics

Hariprasad Vankayalapati
CSO
Bioelexis Therapeutics

Jaimeen Majmudar
Senior Principal Scientist (ChemBio)
Pfizer

Jennifer Petter
Founder & Chief Scientific Officer
Arrakis Therapeutics

Jeremy Edmunds
Executive Director Immunology Chemistry
AbbVie

Monica Schenone
Senior Director, Head Of Chemical Biology and Proteomics
Pfizer

Muneto Mogi
Global Head, Global Discovery Chemistry
Novartis Institutes for BioMedical Research (NIBR)

Rich Heidebrecht
Vice President of Research and Development
Glycologix

Shankar Venkatraman
Executive Director, Chemistry
IFM Therapeutics

Suguna Rachakonda
Vice President, Head of Business Development
Dewpoint Therapeutics

2024 Sponsors

THOUGHT LEADERS

iWuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. http://www.wuxiapptec.com

Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines with our partners by 2025. Sai Life Sciences provides services to our pharma innovator partners, which accelerate the discovery, development and manufacture of complex small molecule therapeutic agents. Our clients gain clear competitive advantages through shorter time to market and risk minimization using our integrated and high-quality scientific services. Established in 1999, Sai has over 2,000 employees located at six R&D and manufacturing sites in India, the UK and USA. As one of India's fastest growing CDMOs, the company is investing over US $ 150 M in augmenting its R&D and manufacturing capabilities, including setting up a Biology Lab in Cambridge, Mass. (USA) and a Process R&D Lab in Manchester, UK. Sai provides high value integrated services in all areas of chemistry from hit discovery to GMP manufacturing, pharmacology, DMPK, toxicology and formulation development to better support the increasing needs of our customers. Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.

CO-HOST SPONSORS

Iktos is a leading 'AI for de novo drug design' company with offices in France, UK and the US and presence in Japan. Iktos technology is built upon the latest developments in deep learning algorithms, for de novo design and AI-driven synthesis planning. Founded in 2016, Iktos has a portfolio of 60 plus real world projects either completed or ongoing. Iktos's customizable technology offers multiple proprietary algorithms to clients, including large/medium pharma, biotech companies and research institutes globally.

Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological study data and chemical structures, and to collaborate with partners through a straightforward web interface. https://www.collaborativedrug.com

Piramal Pharma Solutions (PPS) is a Contract Research Development and Manufacturing Organization (CDMO) offering end-to-end discovery, development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. The Discovery Services site of PPS has been operational since 2003 in Ahmedabad, India and currently have ~300+ chemistry FTE's and ~25 Biologists supporting various small molecule discovery programs in Hit to Lead and Lead Optimization stages and work on both FTE and Fee Based Models. Our capabilities include: • Custom Synthesis of individual compounds, building blocks, scaffolds, focused libraries (40-100 compounds), reference standards, intermediates, impurities & metabolites • DMPK • Route Scouting leveraging our global process chemistry expertise across US, Canada & India to support early drug development • Analytical services including method development (non-GMP), separation of Chiral/ Achiral compounds (mg-gm scale) PPS also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product from 14 sites in India, UK, Canada and USA. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide. PPS is a subsidiary of the India based Healthcare and Financial Conglomerate -Piramal Enterprises Ltd (Market Cap - $5 Billion) and the Carlyle Group has recently acquired a 20% stake in PPS. For more information please visit: www.piramalpharmasolutions.com

PARTNERING SPONSORS

Revvity Signals Software formerly known as PerkinElmer Informatics offers one of the most comprehensive suites of scientific software in the world. Our future-proof technology enables investigators in Life Sciences to capture and analyze their data from initial research and development of their therapeutics, through biomarker discovery & patient stratifications and ultimately live tracking of their clinical trials. From our internationally recognized flagship ChemDraw® to our Signals Research Suite (Signals Notebook, Signals VitroVivo, and Signals Inventa)to our exclusive TIBCO® Spotfire® partnership that brings scientific data analytics to visual life in both

Pelago Bioscience is a Discovery Research Partner focusing on biologically relevant systems, unleashing drug discovery projects using the patented CETSA® technology as a core pillar. The Cellular Thermal Shift Assay (CETSA® by Pelago Bioscience) has multiple assay formats that make it a keystone of decision making throughout the drug discovery pipeline. Unlike other solutions on the market today, its unique approach allows the assessment and quantification of target engagement under physiological conditions – without the need to modify the compound or protein. This provides data that is both actionable and biologically relevant. Think of CETSA® as snapshots of true target engagement inside the cell, any time you need them. Using CETSA® data and applications, our customers are able to make better and more informed decisions at earlier stages in their projects. omers love Sapio's platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs.

Sapio Sciences mission is to improve life in the lab - because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware (TM) lab informatics platform combining cloud-based LIMS, ELN, and data solutions. Sapio serves some of the largest global and niche brands, including biopharma, CRO's and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, stability, clinical, histopathology, drug research, and in vivo studies. Our customers love Sapio's platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs.

Evotec is uniquely positioned to discover the next generation of drugs with higher efficacy and probability of success through our industrialized PanOmics approach towards molecular disease understanding and E.iPSC disease modeling platform. With this state-of-the-art toolbox, powered by AI and the expertise of our scientists, we are a driving force in drug discovery. Our Drug Discovery Integrated Tool Box includes the full spectrum of platforms to support you drug discovery programs: • Target ID & Validation • Hit Identification • Structural Biology • Molecular Design & MedChem • In Vitro Biology • In Vivo Pharmacology • Biomarkers • Bio Reagents & Cellular Sciences • Safety Assessment • Early Formulation • Sample Management • E.iPSC • PanOmics • E.MPD • ADME PK • Antibodies

Red Glead Discovery is a leading and sustainable Scandinavian Drug Discovery Partner with experienced co-workers and with a focus on small molecule- and peptide-based therapeutics. Our research platform comprises medicinal chemistry, synthesis, computational science, biology, ADME and fragment-based lead discovery (WAC™, DSF, and NMR), enabling tailored customer projects. High-quality in vivo PK/pharmacology, X-ray crystallography and cellular target engagement services are available for integrated projects via trusted and often local partners. Our track record contains several examples of successful collaborations with customers from hit finding and lead discovery up to delivery of candidate compounds progressed into preclinical and clinical development.

AI Services: Predictive modelling for drug discovery and optimization using proprietary algorithms and commercial software. Capabilities include target ID-hit-to-lead and lead optimization, virtual screening, and structure-activity relationship (SAR) analysis. Access to high-performance computing (Nvidia H100 cluster) enables rapid iteration and exploration of large chemical spaces. Supported by comprehensive datasets, proprietary HTS small molecule and RNAi library, custom assay development, cell painting and validation capabilities tailored to accelerate drug development.

Aragen Life Sciences (formerly, GVK BIO), is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. It offers end-to-end integrated or standalone solutions for small and large molecules. Established in 2001, the Company operates through a network of sites located globally with a team of 3000+ scientists and 450+ PhDs. Its expertise and experience have enabled over 450 customers in advancing their research programs from discovery through commercialization. Aragen's innovative mindset, infrastructure, flexible business models have enabled us to serve large pharma, biotech, agrochemical, animal health, and performance chemical industries globally. Visit www.aragen.com for more details.

Founded in 1996 and headquartered in Irvine, California, BioDuro-Sundia is a leading US-based CRDMO. With 2,000+ scientists, we have 7 sites across the US and China. We provide fully integrated services spanning drug discovery to commercial manufacturing, covering medicinal chemistry, biology, DMPK, drug substance, and drug product development. Our expertise includes various modalities such as small molecules, peptides, oligonucleotides, and antibody-drug conjugates (ADCs). The drug discovery team, with 1,100+ chemists, serves 330+ global clients annually, offering accelerated project timelines with <5 days per step and a 99%+ on-time delivery record.

Inductive Bio's ADMET Machine Learning (ML) platform accelerates compound optimization, helping medicinal chemists identify the best development candidates. With real-time ADMET liability evaluation, Inductive's platform guides critical design and prioritization decisions toward the most promising ideas. Trained on thousands of data points from proprietary consortium programs, in-house generation, and curated public sources, Inductive's ADMET foundation models empower partners to design high-quality compounds and reduce time to key milestones.

KEY OPINION LEADERS

Agenda at a Glance

MEDICINAL CHEMISTRY
STRATEGY MEETING EAST COAST USA 2024
Wednesday, 13th November 2024 | Le Méridien Boston Cambridge

TIME EST	TRACK 1 AI/ML	TRACK 2 INNOVATIVE AND EMERGING MODALITIES	TRACK 3 CHEMICAL BIOLOGY, TARGETED PROTEIN DEGRADATION AND UNDRUGGABLES	TRACK 4 HIT IDENTIFICATION / LEAD OPTIMIZATION	TRACK 5 DESIGN & SYNTHESIS	TRACK 6 INTEGRATED DRUG DISCOVERY
BOARDROOM ►	Jerome C. Hunsaker A	Jerome C. Hunsaker B	Jerome C. Hunsaker C	Edward Pennell Brooks	Margaret L.A. Macvicar	Lan Jen Chu
08:00 - 08:30	BREAKFAST & REGISTRATION					
08:30 - 09:00	OPENING KEYNOTE PRESENTATION: Transforming Drug Discovery: The Convergence of AI, Machine Learning, and Computational Sciences — Hariprasad Vankayalapati, *CSO*, Bioelexis Therapeutics					
09:00 - 10:00 PHARMA/ BIOTECH	**Looking into the Pivotal Role of AI in Drug Discovery** — Diane Joseph-McCarthy, *Executive Director, Bioengineering Technology & Entrepreneurship Center*, Boston University	**Challenges and solutions in the hit-to-lead phase: ensuring efficacy and safety in drug development** — Benoit Moreau, *Head of Medicinal Chemistry*, Remix Therapeutics	**Molecular Glue Targeted Protein Degradation on Undruggable targets** — Hariprasad Vankayalapati, *CSO*, Bioelexis Therapeutics	**From Hits to Leads: Advanced Strategies and Technologies for Enhancing Drug Discovery in the Initial Phases** — Rich Heidebrecht, *Vice President of Research and Development*, Glycologix	**Streamlining the hit-to-candidate process: Strategies to most effectively advance chemical matter from hit to clinical candidate** — Shankar Venkatraman, *Executive Director, Chemistry*, IFM Therapeutics	**Addressing the Unmet Needs in CNS Drug Discovery: New Paradigms in Target Identification and Drug Development** — Alex Nivorozhkin, *Chief Scientific Officer*, Cybin
10:00 - 10:05	REFRESHMENT BREAK					
10:05 - 10:25	NETWORKING / 1-1 MEETINGS					
10:25 - 10:45	NETWORKING / 1-1 MEETINGS					
10:45 - 11:05	NETWORKING / 1-1 MEETINGS					
11:10 - 12:10 SOLUTION		**Pioneering the Future: Harnessing Innovative Modalities in Medicinal Chemistry** — Zev Wisotsky, *Director, New Modality Drug Discovery Solutions*, Revvity Signals — REVVITY SIGNALS	**Targeted Protein Degradation** — Dr. Tao Guo, *SVP and Head of WuXi Chemistry – Research Chemistry Services Business Development and Integrated Program Management*, WuXi AppTec — WUXI APPTEC	**Lead Optimisation for bRO5 Molecules** — Vicky Steadma, *Vice President Business Development and Integrated Partnerships*, Sai Life Sciences — SAI LIFE SCIENCES	**Improving Efficiency in Design and Synthesis** — Kelly Barret, *Director of Discovery Business Development*, Sai Life Sciences — SAI LIFE SCIENCES	
12:15 - 13:15 PHARMA/ BIOTECH	**The application of Generative Design to advance drug discovery projects** — Jeremy Edmunds, *Executive Director Immunology Chemistry*, AbbVie	**Strategic Innovations in Medicinal Chemistry: New Paradigms for Hit Identification and Lead Refinement** — Brian Sparling, *Director, Head of Medicinal Chemistry*, Accent Therapeutics	**Exploring the Current Formulation Challenges in Undruggable Leads** — Ed Olhava, *Senior Vice President, Preclinical Development*, IFM Therapeutics	**H2LOptimization: Oral Small Molecule Agonists/Activators** — Hariprasad Vankayalapati, *CSO*, Bioelexis Therapeutics	**Transforming the Future of Drug Discovery: Integrative Design and Synthesis Approaches in Medicinal Chemistry for Novel Therapeutics** — Allen Hopper, *VP Drug Discovery*, Lucy Therapeutics	**RNA as a Drug Target: Breakthroughs and Challenges in Small Molecule Approaches** — Jennifer Petter, *Founder & Chief Scientific Officer*, Arrakis Therapeutics
13:15 - 14:00	NETWORKING LUNCH					
14:00 - 14:20	NETWORKING / 1-1 MEETINGS					
14:20 - 14:40	NETWORKING / 1-1 MEETINGS					
14:40 - 15:10	AFTERNOON KEYNOTE PRESENTATION; Application of High Throughput Experimentation and Flow Chemistry to Accelerate Drug Discovery — PRESENTER: Dr. Tao Guo, *SVP and Head of WuXi Chemistry – Research Chemistry Services Business Development and Integrated Program Management*, WuXi AppTec					
15:10 - 16:10 PHARMA/ BIOTECH	**Leveraging Generative Modeling to Accelerate Drug Discovery – What are current state-of-art technologies?** — Muneto Mogi, *Global Head, Global Discovery Chemistry*, Novartis Institutes for BioMedical Research (NIBR)	**Revolutionizing Healthcare: How Small Molecules are Shaping the Future of Emerging Therapeutic Modalities** — Bruce Ellsworth, *Head of Oncology East & BBRC Medicinal Chemistry*, Bristol Myers Squibb	**Unraveling Protein Targets in Disease: Proteomic Approaches to Drug Development** — Monica Schenone, *Senior Director, Head Of Chemical Biology and Proteomics*, Pfizer	**The Evolution of Hit-to-Lead Paradigms: Combining Traditional Approaches with Modern Innovations in Small Molecule Research** — Blaise Lippa, *Chief Scientific Officer*, Morphic Therapeutic		**Topic TBC** — Jaimeen Majmudar, *Senior Principal Scientist (ChemBio)*, Pfizer
16:10 - 16:15	AFTERNOON REFRESHMENT BREAK					
16:15 - 16:45	KEYNOTE PRESENTATION: Integrating CDD Vault into a Serverless Data Platform for Biotech Companies — PRESENTER: Patrick O'Mara, *Associate Director of Research Informatics*, Photys Therapeutics					
16:45 - 17:15	PANEL DISCUSSION: Bridging Science and Investment: A Dialogue on Drug Discovery, Venture Strategies, Biotech Progress, and the Revolutionary Landscape of Pharmaceuticals — CHAIRPERSON: Suguna Rachakonda, *Vice President, Head of Business Development*, Dewpoint Therapeutics; PRESENTER: Rich Heidebrecht, *Vice President of Research and Development*, Glycologix; PRESENTER: Itta MacNevin, *SVP, Head of Business Development North America*, Evotec; PRESENTER: Carlos Pedraza, *AVP Biology & Site Head*, Sai Life Sciences					
17:15 - 18:30	DRINKS & CANAPES RECEPTION					

Event Day | Keynote Presentations

A great way to open the roundtable discussions is through a timely presentation from a top-tier biotech/pharmaceutical company. Listen as we hear this 30-minute exposition on this meeting's pressing topic.

08:30 - 09:00 ET OPENING KEYNOTE PRESENTATION

Transforming Drug Discovery: The Convergence of AI, Machine Learning, and Computational Sciences

Hariprasad Vankayalapati
CSO
Bioelexis Therapeutics

ABOUT THE SPEAKER
Speaker TBC

14:40 - 15:10 EST KEYNOTE PRESENTATION

Application of High Throughput Experimentation and Flow Chemistry to Accelerate Drug Discovery

Dr. Tao Guo
SVP and Head of WuXi Chemistry – Research Chemistry Services Business Development and Integrated Program Management
WuXi AppTec

ABOUT THE SPEAKER
Speaker TBC

16:15 - 16:45 EST AFTERNOON KEYNOTE PRESENTATION

Integrating CDD Vault into a Serverless Data Platform for Biotech Companies

This presentation explores the integration of CDD Vault within a serverless data orchestration pipeline tailored for biotech start-ups. By leveraging Apache Airflow hosted on Google Cloud's Cloud Composer, we automate and streamline data transfers between Egnyte, CDD Vault, and BigQuery. Emphasizing the strengths of CDD Vault, we highlight its integration capabilities with its robust API and intuitive data model. The presentation will demonstrate how this integration enhances data management, accelerates insights, and supports scientific innovation, providing a scalable, secure, and cost-efficient solution for biotech organizations.

Patrick O'Mara
Associate Director of Research Informatics
Photys Therapeutics

ABOUT THE SPEAKER
Patrick O'Mara is an accomplished leader in Information Technology and Biotechnology, currently serving as the Associate Director of Research Informatics at Photys Therapeutics. With over 15 years of experience, he has a proven track record indeveloping strategic IT initiatives that drive digital transformation and enhance scientific workflows. His recent endeavors focus on architecting a cutting-edge informatics ecosystem that supports scientific research. Previously, at Cell Signaling Technology, he led a global team and played a pivotal role in aligning IT strategies with organizational goals while ensuring operational efficiency through effective budget management. A passionate advocate for continuous improvement, Patrick actively engages with industry peers, sharing insights at conferences and contributing to publications on innovative solutions for the biotech sector. Patrick holds a Master's in Bioinformatics from Harvard Extension School.

14:40 - 15:10 EST PANEL DISCUSSION

Bridging Science and Investment: A Dialogue on Drug Discovery, Venture Strategies, Biotech Progress, and the Revolutionary Landscape of Pharmaceuticals

CHAIRPERSON
Suguna Rachakonda
Vice President, Head of Business Development
Dewpoint Therapeutics

PANELIST
Rich Heidebrecht
Vice President of Research and Development
Glycologix

PANELIST
Itta MacNevin
SVP, Head of Business Development North America
Evotec

PANELIST
Carlos Pedraza
AVP Biology & Site Head
Sai Life Sciences

ABOUT THE SPEAKER
Speaker TBC

Event Day

TRACK 1

AI/ML

Large quantities of biological and medical data brought by increased digitalization in the industry go hand in hand with next-level machine cognition to aid efforts involving drug discovery & development, synthesis, drug repurposing, modeling & simulation, predicting protein attachment, computer-Aided drug design (CADD), and beyond. This track explores the verifiable use of advanced technologies to analyze data, predict structure and activity, aid in hit finding and more.

08:00 - 08:30 EST **BREAKFAST & REGISTRATION**

08:30 - 09:00 EST **OPENING KEYNOTE PRESENTATION**
See Page 6

09:00 - 10:00 EST **ROUNDTABLE 1**

Looking into the Pivotal Role of AI in Drug Discovery

- How has AI changing the way drug discovery is being done compared to 10 years ago?
- Where in the discovery pipeline is AI having the biggest impact?
- What are the areas for improvement
- What do you think the next 10 yrs will bring? What will drug discovery of the future look like?

Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

ABOUT THE SPEAKER

Diane Joseph-McCarthy is the Executive Director of the Bioengineering Technology & Entrepreneurship Center and Professor of the Practice in Biomedical Engineering and Chemistry at Boston University. Prior to that, she was a life science executive with over 20 years of drug discovery, development, and leadership experience. She was SVP of Discovery & Early Development at EnBiotix, a bioengineering company focused on respiratory and rare disease. She was an Associate Director at AstraZeneca, where she led a global team in Predictive Science. At Wyeth, she held positions of increasing responsibility. Diane received her PhD from MIT and was a postdoctoral fellow at Harvard University/Harvard Medical School. She is a fellow of the American Institute for Medical and Biological Engineering.

10:00 - 11:05 EST **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

12:15 - 13:15 EST **ROUNDTABLE 3**

The application of Generative Design to advance drug discovery projects

- Deep learning has been introduced to drug discovery to solve issues associated with designing drugs
- Applications include improved potency, desirable ADME properties in addition to synthetic feasibility and patentability
- Does experimental data validate the promise?

Jeremy Edmunds
Executive Director Immunology Chemistry
AbbVie

ABOUT THE SPEAKER

Dr. Jeremy Edmunds joined Immunology Discovery Research at Abbvie in December 2006. Here he leads the small molecule chemistry efforts directed towards creating therapeutics for autoimmune diseases. Jeremy is a chemist by training and as a medicinal chemist creates drugs, rather than hunting for them, and thus isn't a drug hunter. At Abbvie Jeremy leads a multidisciplinary department of medicinal chemists, analytical chemists, and biochemists to create various small molecule compounds to treat autoimmune diseases. His expertise in the application of cheminformatics tools and techniques allowed the creation of a design synthesis orientated medicinal chemistry group that applies cutting edge technologies to the design of therapeutic compounds. As a member of the Immunology leadership team, he has advanced over a dozen small molecule inhibitors into clinical development. Prior to joining Abbvie he worked for Pfizer for over 16 years and was responsible for small molecule drug discovery in the area of cardiovascular disease. There he led the multi-disciplinary acute coronary artery discovery team, which involved creating a portfolio of projects to modulate the underlying biology associated with plaque rupture or clot formation. This work led to clinical studies on thrombin inhibitors and factor Xa inhibitors. While there he also served as an adjunct Professor at the University of Michigan Pharmacy School, where he taught drug design, principally around cardiovascular disease. With over 30 years of drug discovery experience Jeremy has authored greater than 100 articles, patents and presentations related to small molecule drug discovery.

13:15 - 14:40 EST **NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS**

14:40 - 15:10 EST **KEYNOTE PRESENTATION**
See Page 6

15:10 - 16:10 EST **ROUNDTABLE 4**

Leveraging Generative Modeling to Accelerate Drug Discovery – What are current state-of-art technologies?

Muneto Mogi
Global Head, Global Discovery Chemistry
Novartis Institutes for BioMedical Research (NIBR)

ABOUT THE SPEAKER

Dr. Muneto Mogi is the Global Head of Global Discovery Chemistry at Novartis Biomedical Research, where he has worked in various executive leadership and senior research discovery positions in chemistry over nearly 29 years across global organizations in USA, Japan, Germany, and Switzerland. He has contributed over 60 drug discovery projects in different therapeutic areas using various modalities, such as small molecules, peptides, chemical biology conjugates, biomaterials, and polymers. Currently based in Cambridge, Massachusetts USA, he oversees Novartis's discovery chemistry worldwide, which covers diverse disease areas such as oncology, cardiovascular and metabolism, neuroscience, and immunology. Before joining Novartis, he worked at Shionogi and Bayer Healthcare in Japan. Dr. Mogi obtained his BA in Chemistry from Boston University and received his Ph.D. in Pharmaceutical Sciences from Kyoto Pharmaceutical University.

16:10 - 16:15 EST **AFTERNOON REFRESHMENT BREAK**

16:15 - 16:45 EST **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

16:45 - 17:15 EST **PANEL DISCUSSION**
See Page 6

17:15 - 18:30 EST **DRINKS & CANAPES RECEPTION**

Event Day

TRACK 2

Innovative and Emerging Modalities

Despite the reinvigorated R&D engine and reinstated productivity, challenges and opportunities remain unanswered such as optimized druggability, pharmacokinetics and safety, enhanced bioavailability, DNA-Encoded Library, Small and Large Molecules Enhancement, Covalent Fragment Libraries, and more. This track aims to tackle these current barriers, formulate an outlook strategy and explore the emerging modality space.

08:00 - 08:30 EST **BREAKFAST & REGISTRATION**

08:30 - 09:00 EST **OPENING KEYNOTE PRESENTATION**
See Page 6

09:00 - 10:00 EST **ROUNDTABLE 1**

Challenges and solutions in the hit-to-lead phase: ensuring efficacy and safety in drug development

- Type of assays used primarily during HTL, improvements to workflow
- Steps taken during HTL phase to understand MOA, PD/efficacy, off-target/safety
- Level of derisking required during HTL phase before transitioning to LO

Benoit Moreau
Head of Medicinal Chemistry
Remix Therapeutics

ABOUT THE SPEAKER

Benoit Moreau is the head of medicinal chemistry at Remix Therapeutics, a biotech focused on controlling gene and protein expression through modulation of RNA processing. He has over 15 years of experience in drug discovery, building and leading teams in medicinal chemistry at Boehringer Ingelheim, Tarveda and Syros. He contributed to the discovery of several clinical candidates on projects across virology, oncology and rare genetic diseases. He received his PhD in synthetic chemistry from Université de Montréal and completed postdoctoral studies at Harvard University.

10:00 - 11:10 EST **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

11:10 - 12:10 EST **SOLUTION FOCUS ROUNDTABLE 2**

Pioneering the Future: Harnessing Innovative Modalities in Medicinal Chemistry

- Navigating the Cross-Modality Landscape
- Balancing Innovation with Safety
- The Challenge of Software that Speaks Multimodal Drug Discovery
- The Evolving Role of Medicinal Chemists
- Bringing Emerging Modalities to Underserved Diseases

Zev Wisotsky
Director, New Modality
Drug Discovery Solutions
Revvity Signals

ABOUT THE SPEAKER

Zev Wisotsky is Director, New Modality Drug Discovery Solutions at Revvity Signals. Zev has 10+ years experience supporting Pharma and Biotech informatics and data strategies. He has a Ph.D. in Neuroscience from University of California Riverside.

12:15 - 13:15 EST **ROUNDTABLE 3**

Strategic Innovations in Medicinal Chemistry: New Paradigms for Hit Identification and Lead Refinement

- Strategy and tactics for finding chemical matter for novel targets/protein classes
- Role of predictive tools/AI in hit expansion and lead refinement
- Emerging technologies to enable the advancement of chemical matter

Brian Sparling
Director, Head of Medicinal Chemistry
Accent Therapeutics

ABOUT THE SPEAKER
Speaker TBC

13:15 - 14:40 EST **NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS**

14:40 - 15:10 EST **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

15:10 - 16:10 EST **ROUNDTABLE 4**

Revolutionizing Healthcare: How Small Molecules are Shaping the Future of Emerging Therapeutic Modalities

- Expanding therapeutic options with emerging and mixed modalities
- Matching modality to mechanism of action – selecting a strategy for a desired pharmacology and patient opportunity
- Next wave innovation for translationally relevant modality strategies

Bruce Ellsworth
Head of Oncology East & BBRC Medicinal Chemistry
Bristol Myers Squibb

ABOUT THE SPEAKER
Speaker TBC

16:10 - 16:15 EST **AFTERNOON REFRESHMENT BREAK**

16:15 - 16:45 EST **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

16:45 - 17:15 EST **PANEL DISCUSSION**
See Page 6

17:15 - 18:30 EST **DRINKS & CANAPES RECEPTION**

Event Day

TRACK 3

Chemical Biology, Targeted Protein Degradation and Undruggables

This track tackles pressing topics that interrogate and discern biological function by exploring small and large molecule modulation, undruggable targets, Target Protein Degradation, Deep Learning, And Molecular Simulations, and more, to understand probe development better and uncover novel and therapeutically relevant targets.

08:00 - 08:30 EST BREAKFAST & REGISTRATION

08:30 - 09:00 EST OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 EST ROUNDTABLE 1

Molecular Glue Targeted Protein Degradation on Undruggable targets

Hariprasad Vankayalapati
CSO
Bioelexis Therapeutics

ABOUT THE SPEAKER
Speaker TBC

10:00 - 11:10 EST REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 EST SOLUTION FOCUS ROUNDTABLE 2

Targeted Protein Degradation

- What is the best strategy to targeted protein degradation
- How to implement the strategy
- "Direct to Biology" to accelerate PROTAC discovery

Dr. Tao Guo
SVP and Head of WuXi Chemistry – Research Chemistry Services Business Development and Integrated Program Management
WuXi AppTec

ABOUT THE SPEAKER
Dr. Tao Guo is SVP and Head of WuXi Chemistry – Research Chemistry Services Business Development and Integrated Program Management, WuXi AppTec. He has over 30 years of experience in drug discovery. He was trained as an organic chemist with PhD from Columbia University and PostDoc from UC Berkeley. He is the recipient of 43 issued US patents and an inventor of 10 clinical candidate compounds with 1 approved by FDA.

12:15 - 13:15 EST ROUNDTABLE 3

Exploring the Current Formulation Challenges in Undruggable Leads

Ed Olhava
Senior Vice President, Preclinical Development
IFM Therapeutics

ABOUT THE SPEAKER
Over his nearly 20 year career in mid and early-stage biotech, **Ed Olhava** has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology, safety and CMC to enter clinical trials with these novel entities. Before joining IFM, Ed was a strategic advisor at Third Rock Ventures, where he developed the strategic and operational plans for the drug discovery groups of two Third Rock seed companies, both of which were successfully funded and launched. Prior to Third Rock, he was a founding scientist at Epizyme, joining the company as the first medicinal chemist. He started the medicinal chemistry group and invented Epizyme's first clinical compound and the first clinical histone methyltransferase inhibitor, EPZ-5676, leading activities from hit finding to filing the Investigational New Drug application. Before joining Epizyme, Ed began his medicinal chemistry career at Millennium Pharmaceuticals, where he co-invented NINLARO, approved in 2015 for the treatment of multiple myeloma, and MLN-4924. Ed obtained his Ph.D. in synthetic organic chemistry from Harvard University and B.S. in chemistry from Stanford University. He is co-author/inventor on more than 40 papers and patents.

13:15 - 14:40 EST NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 EST AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 EST ROUNDTABLE 4

Unraveling Protein Targets in Disease: Proteomic Approaches to Drug Development

- Nominating protein pairs for proximity Induced Pharmacology
- Using Proteomics for Target CiR
- Degron mapping with proteomics; are we there?

Monica Schenone
Senior Director, Head Of Chemical Biology and Proteomics
Pfizer

ABOUT THE SPEAKER
Monica Schenone is the Head of Chemical Biology and Proteomics at Pfizer. Her team supports all therapeutic areas focusing on target engagement and selectivity of drug leads and candidates in live cell systems. The group has a strong emphasis on method and platform development to support drug discovery. Prior to joining Pizer she led the interactomics group in the Proteomics Platform at The Broad Institute of MIT and Harvard. Monica graduated from the University of Buenos Aires, Facultad de Ciencias Exactas, as a Licenciada in Chemistry. She did her PhD in Biochemistry at the University of Notre Dame and her post-doctoral work at Beth Israel Deaconess Medical Center.

16:10 - 16:15 EST AFTERNOON REFRESHMENT BREAK

16:15 - 16:45 EST AFTERNOON KEYNOTE PRESENTATION
See Page 6

16:45 - 17:15 EST PANEL DISCUSSION
See Page 6

17:15 - 18:30 EST DRINKS & CANAPES RECEPTION

Event Day

TRACK 4

Hit Identification / Lead Optimization

The process of discerning the properties associated with each hit compound is multi-dimensional and impossibly challenging giving rise to the process of eliminating weekly active compounds - Hit to Lead. This track will investigate the steps between target validation to lead optimization, Structure-Based Drug Design Lead, High Throughput Screening, Accelerating Hit-To-Lead Optimization and Progress of Compounds for Lead Optimization, and more.

08:00 - 08:30 EST **BREAKFAST & REGISTRATION**

08:30 - 09:00 EST **OPENING KEYNOTE PRESENTATION**
See Page 6

09:00 - 10:00 EST **ROUNDTABLE 1**

From Hits to Leads: Advanced Strategies and Technologies for Enhancing Drug Discovery in the Initial Phases

- Matching optimization activities with business goals
- Identify the gaps between lead performance and the requisite profile
- Develop general SAR while working on target issues
- Balance between strategy and carefully chosen technologies
- Optimization activities should evolve with the project

Rich Heidebrecht
Vice President of Research and Development
Glycologix

ABOUT THE SPEAKER
Rich Heidebrecht is currently the Vice President of Research and Development at Glycologix. He started his career at Pfizer and Merck before making a transition to Biotech via the Broad Institute. Rich has gained expertise in medicinal, process and analytical chemistry and has worked on diverse therapeutic modalities such as small molecules, cell therapies, medical devices, and polymers including oligonucleotides. Over the course of his career, Rich has contributed to 35 patent/ patent applications, 16 papers, two clinical programs and one marketed drug. Doctor Heidebrecht completed his undergraduate work at Worcester Polytechnic Institute and his graduate work at Indiana University with David R. Williams. His postdoc with Stephen Martin at the University of Texas at Austin rounded out two natural product synthesis projects - one total, one formal.

10:00 - 11:10 EST **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

11:10 - 12:10 EST **SOLUTION FOCUS ROUNDTABLE 2**

Lead Optimisation for bRO5 Molecules

- Protac, Macrocycles, peptides, etc.
- Managing Phys-Chem properties
- Best assays to characterize these molecules
- Computational approaches to support lead optimisation for bRO5 molecules

Vicky Steadman
Vice President Business Development and Integrated Partnerships
Sai Life Sciences

ABOUT THE SPEAKER
Dr. Vicky Steadman is Vice President Business Development and Integrated Partnerships at Sai Life Sciences. A medicinal chemist by background, Vicky has nearly 20 years industry experience in Big Pharma and within CROs. She is named on over 25 peer reviewed publications and patents including a Nature paper and has worked in the therapeutic areas of anti-virals, antibiotics and neuroscience. Vicky has a BSc in chemistry from Imperial College and a PhD in organic chemistry from the University of Cambridge. She is a fellow of the Royal Society of Chemistry.

12:15 - 13:15 EST **ROUNDTABLE 3**

H2LOptimization: Oral Small Molecule Agonists/ Activators

Hariprasad Vankayalapati
CSO
Bioelexis Therapeutics

ABOUT THE SPEAKER
Hari is a co-founder, currently serving as Chief Scientific Officer of Biolexis Therapeutics, Inc., a clinical stage Biopharmaceutical company, discovering and developing novel, first-in-class small molecule targeted therapeutics for cancers, immune-mediated, auto-immune, inflammatory and metabolic diseases. Hari and his colleague Dr. David J. Bearss together developed the empirical-driven MolecuLernTM technology that has empirical/ experimental data implemented in ML algorithms, accelerating drug discoveries, and successfully translating novel agents into clinical stage of development. Hari, after his decade of academic career, recently moved back to the pharmaceutical industry. Hari is the key in creating seven clinical agents: MP-470/Amuvatinib, SGI-1776, SGI-110/ Guadecitabine, HCI-2577/SP-2577, HCI-2084/TP-0903, ARN-6039/BOS-172767/SLX-0528, ARN-3236/GRN-300 currently in various stages of clinical development. Hari received his Ph.D., and M. Pharm degrees in Medicinal Chemistry from the Institute of Chemical Technology (formerly UDCT) of the University of Mumbai and the University of Karnataka in India. His Postdoctoral training was in University of Sunderland in England and at the University of Arizona Cancer Center under Prof. Laurence H. Hurley. Hari is an author of ~100 plus publications, presentations, and he is an inventor of several issued/ published US/WO patents.

13:15 - 14:40 EST **NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS**

14:40 - 15:10 EST **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

15:10 - 16:10 EST **ROUNDTABLE 4**

The Evolution of Hit-to-Lead Paradigms: Combining Traditional Approaches with Modern Innovations in Small Molecule Research

- Best screening technologies to screen for difficult targets
- How to advance when no competitive binding tools are available
- Key new technologies to advance hits to a lead

Blaise Lippa
Chief Scientific Officer
Morphic Therapeutic

ABOUT THE SPEAKER
Blaise Lippa is the CSO of Morphic Therapeutic, joining the company at its inception and helping to build it through IPO, while advancing the lead asset through phase 2 POC efficacy. Prior to this, Blaise was a Sr. Director of medicinal chemistry at Cubist and served on a development team that achieved an NDA. Blaise began his career at Pfizer, working in oncology, antibacterials, and metabolic diseases. A project he initiated and first led was approved in 2019 (Daurismo/ Glasdegib) for leukemia. Blaise obtained his B.Sc. degrees in biology and chemistry from the University of Michigan, and his Ph.D. from Stanford.

16:10 - 16:15 EST **AFTERNOON REFRESHMENT BREAK**

16:15 - 16:45 EST **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

16:45 - 17:15 EST **PANEL DISCUSSION**
See Page 6

17:15 - 18:30 EST **DRINKS & CANAPES RECEPTION**

Event Day

TRACK 5

Design & Synthesis

Tagline

08:00 - 08:30 EST BREAKFAST & REGISTRATION

08:30 - 09:00 EST OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 EST ROUNDTABLE 1

Streamlining the hit-to-candidate process: Strategies to most effectively advance chemical matter from hit to clinical candidate

Shankar Venkatraman
Executive Director, Chemistry
IFM Therapeutics

ABOUT THE SPEAKER

Over his 20+ year industrial career Shankar Venkatraman has invented and progressed multiple compounds through discovery and into clinical development. He has focused on discovering first-in-class small molecule modulators of new biological pathways, closely integrating medicinal chemistry, pharmacology and safety to enter clinical trials with these novel entities. Before joining IFM Therapeutics, LLC, Shankar was a Director of Chemistry at Vitae Pharmaceuticals. There he led number of programs including Menin-MLL, resulting in Revumenib (SNDX-5613), currently undergoing multiple clinical trials for ALL/AML with an anticipated NDA filing by June of 2024. Prior to Vitae, he was a Senior Research Fellow at Merck, where he worked on number of modalities including HIV, neuropathic pain and schizophrenia, and delivered number of clinical candidates. Before joining Merck, Shankar began his medicinal chemistry career at Axys Pharmaceuticals, and worked on cathepsin K , with efforts leading to the identification of Odanacatib a phase 3 canddiate. Shankar obtained his Ph.D. in synthetic organic chemistry from University of Minnesota and B.S. in chemistry from University of Bombay. He is co-author/inventor on more than 60 papers and patents.

10:00 - 11:10 ET REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 ET SOLUTION FOCUS ROUNDTABLE 2

Improving Efficiency in Design and Synthesis

- How to use AI for understanding synthetic tractability
- Impact of Alpha fold on Structure Based Drug Desing
- Synthetic efficiency on nano scales
- Direct2Biology approaches
- AI for SAR analysis

Kelly Barret
Director of Discovery Business Development
Sai Life Sciences

ABOUT THE SPEAKER

Speaker TBC

12:15 - 13:15 EST ROUNDTABLE 3

Transforming the Future of Drug Discovery: Integrative Design and Synthesis Approaches in Medicinal Chemistry for Novel Therapeutics

Allen Hopper
VP Drug Discovery
Lucy Therapeutics

ABOUT THE SPEAKER

Allen Hopper received his Ph.D. in Medicinal Chemistry from the Ohio State University in 1993 under the mentorship of Professor D. T. Witiak, followed by a post-doc at the University of Wisconsin. Prior to joining Lucy Therapeutics in 2022, Allen held positions for a variety of Biotech companies including Allelix, Memory, Lundbeck and Sage Therapeutics. Most of his career has been in the area of small molecule CNS drug discovery focused on compound design and building mechanistic links from target engagement to disease relevant biological consequences. Allen authored or co-author approximately 75 patent applications and publications.

13:15 - 14:40 EST NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 EST AFTERNOON KEYNOTE PRESENTATION
See Page 6

16:10 - 16:15 EST AFTERNOON REFRESHMENT BREAK

16:15 - 16:45 EST AFTERNOON KEYNOTE PRESENTATION
See Page 6

16:45 - 17:15 EST PANEL DISCUSSION
See Page 6

17:15 - 18:30 EST DRINKS & CANAPES RECEPTION

Event Day

TRACK 6

Integrated Drug Discovery

Overcoming the high attrition rates of the development process, particularly in drug discovery and optimization remains a significant hurdle and a top priority in the pharma and biotech sector. Here we will explore effective strategies to break down discipline segmentation and foster an improved integrated approach to drug discovery.

08:00 - 08:30 EST BREAKFAST & REGISTRATION

08:30 - 09:00 EST OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 EST ROUNDTABLE 1

Addressing the Unmet Needs in CNS Drug Discovery: New Paradigms in Target Identification and Drug Development

- Polypharmacology, Targeting and Rational Drug Design of the CNS Drugs
- Drug Delivery to the Brain
- Clinical Trials Designs in Psychiatry (placebo effects, arrival of ketamine and psychedelics

Alex Nivorozhkin
Chief Scientific Officer
Cybin

ABOUT THE SPEAKER
Speaker TBC

10:00 - 11:10 EST REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

12:15 - 13:15 EST ROUNDTABLE 3

RNA as a Drug Target: Breakthroughs and Challenges in Small Molecule Approaches

Jennifer Petter
Founder & Chief Scientific Officer
Arrakis Therapeutics

ABOUT THE SPEAKER
Speaker TBC

13:15 - 14:40 EST NETWORKING LUNCH & NETWORKING / 1-1 MEETINGS

14:40 - 15:10 EST AFTERNOON KEYNOTE PRESENTATION
See Page 6

15:10 - 16:10 EST ROUNDTABLE 4

Topic TBC

Jaimeen Majmudar
Senior Principal Scientist (ChemBio)
Pfizer

ABOUT THE SPEAKER
Speaker TBC

16:10 - 16:15 EST AFTERNOON REFRESHMENT BREAK

16:15 - 16:45 EST AFTERNOON KEYNOTE PRESENTATION
See Page 6

16:45 - 17:15 EST PANEL DISCUSSION
See Page 6

17:15 - 18:30 EST DRINKS & CANAPES RECEPTION



Pharma
FEATURES

Find your new partner,
explore our digital storefronts

www.pharmafeatures.com

Contact us to discuss how we can help generate growth for your business

Dex Marco Guibelondo
Marketing Content Writer, Proventa International
Editor-in-Chief, PharmaFEATURES

dex@proventainternational.com

PROVENTA INTERNATIONAL

2025 Strategy Meeting Calendar

MAY

Boston/Cambridge MA - US East Coast

MAY 7 WED
CHEMISTRY MANUFACTURING CONTROL
CMC Strategy Meeting 2025
Le Meridien Boston Cambridge

MAY 8 THUR
MEDICINAL CHEMISTRY
Medicinal Chemistry Strategy Meeting 2025
Le Meridien Boston Cambridge

Princeton/New Jersey - US East Coast

MAY 14 WED
MEDICINAL CHEMISTRY
Medicinal Chemistry Strategy Meeting 2025
Hyatt Regency Princeton

MAY 15 THUR
CLINICALOPERATIONS & CLINICALTRIALSUPPLYCHAIN
Clinical Operations & Clinical Trial Supply Chain Strategy Meeting 2025
Hyatt Regency Princeton

NOVEMBER

San Diego - US West Coast

NOV 12 WED
MEDICINAL CHEMISTRY
Medicinal Chemistry Strategy Meeting 2025
Hard Rock Hotel San Diego

NOV 13 THUR
CLINICALOPERATIONS & CLINICALTRIALSUPPLYCHAIN
Clinical Operations & Clinical Trial Supply Chain Strategy Meeting 2025
Hard Rock Hotel San Diego

Boston/Cambridge MA - US East Coast

NOV 18 TUE
CLINICALOPERATIONS & CLINICALTRIALSUPPLYCHAIN
Clinical Operations & Clinical Trial Supply Chain Strategy Meeting 2025
Le Meridien Boston Cambridge

NOV 19 WED
BIOINFORMATICS & DRUG DISCOVERY BIOLOGY
Bioinformatics Strategy Meeting 2025
Le Meridien Boston Cambridge

MEDICINAL CHEMISTRY

STRATEGY MEETING EAST COAST USA 2024

Wednesday, 13th November 2024 | Le Méridien Boston Cambridge

Hotel & Venue

Le MERIDIEN

Le Méridien Boston Cambridge

Le Méridien Cambridge-MIT's elegant guest rooms and suites offer a place of luxurious sanctuary and unmatched comfort. Explore unique programs inspired by the brand's European heritage. Born in a glamorous era of travel, Le Méridien believes everyone should explore the world in style.

Hotel Details > | Map & Directions >




OUR FACE TO FACE MEETING IN OCT & NOV 2024

STRATEGY MEETING EUROPE
Crowne Plaza, London Docklands

OCT 23
MEDICINAL CHEMISTRY
STRATEGY MEETING EUROPE 2024

STRATEGY MEETING EAST COAST USA
Le Meridien Boston Cambridge

NOV 11
BIOINFORMATICS & IT
STRATEGY MEETING EAST COAST USA 2024

NOV 12
DRUG DISCOVERY BIOLOGY
STRATEGY MEETING EAST COAST USA 2024

NOV 13
MEDICINAL CHEMISTRY
STRATEGY MEETING EAST COAST USA 2024

Visit us on our website to know more about our meetings

www.proventainternational.com